MNTA’s 12/31/15 pro forma cash balance=$416M; this consists of $350M unrestricted cash, $21M of restricted cash (http://finance.yahoo.com/news/momenta-pharmaceuticals-reports-fourth-quarter-130000067.html ), and $45M received from MYL in early January as the up-front amount in the companies’ FoB collaboration (#msg-119689602).